Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) in Patients With CD30-Positive Hematologic Malignancies: CYP3A4 Drug-Drug Interactions, Excretion, and Special Populations

NCT01026415 is registered in ClinicalTrials.gov with Seagen Inc. as lead sponsor.

NCT NCT01026415
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01026415 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) in Patients With CD30-Positive Hematologic Malignancies: CYP3A4 Drug-Drug Interactions, Excretion, and Special Populations
Lead sponsor
Seagen Inc.
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2009
Completion date
May 31, 2012
Enrollment
73 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

carcinomas, disease, hodgkin, lymphoma, large-cell, anaplastic, lymphoma, non-hodgkin, neoplasms